Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.0K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.0K
Disorders of Leukocytes01:27

Disorders of Leukocytes

992
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
992
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Expanding Role of Indole Scaffolds in Combating Antimicrobial Resistance.

Drug development research·2026
Same author

Sustainable diets and functional foods for the prevention of cardio-metabolic diseases and sustainable development goals of the UNO. An international consensus of scientific statement of the international college of nutrition and 28th world congress on clinical nutrition, Bogor, Indonesia.

BMC cardiovascular disorders·2026
Same author

Design and Development of a Novel LXRβ/PPARδ Dual Agonist for Memory Impairment and Pathology in 3xTg-AD Animal Model of Alzheimer's Disease.

ACS chemical biology·2026
Same author

Outcomes of PTCY-Based Haploidentical Transplants and Donor Factors Affecting Outcomes: A 12-year Experience from India.

Blood cell therapy·2026
Same author

Introduction to cancer biomarkers and current research.

Advances in cancer research·2026
Same author

Identification of the Novel HLA-B*44:03:02:08 Allele in an Individual From Eastern India.

HLA·2026

Related Experiment Video

Updated: Jul 29, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K

NK cell defects: implication in acute myeloid leukemia.

Selma Z D'Silva1, Meenakshi Singh1,2, Andrea S Pinto1

  • 1Transplant Immunology and Immunogenetics Lab, Advanced Centre for Treatment, Education and Research in Cancer (ACTREC), Tata Memorial Centre, Navi Mumbai, India.

Frontiers in Immunology
|May 25, 2023
PubMed
Summary
This summary is machine-generated.

Natural Killer (NK) cell defects hinder anti-leukemia responses in Acute Myeloid Leukemia (AML). Current NK cell therapies show promise but require further research to overcome relapse and improve outcomes for AML patients.

Keywords:
AMLBiKEsCAR-NKTriKEsimmunotherapynatural killer cells

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

191
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Related Experiment Videos

Last Updated: Jul 29, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.0K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

191
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Acute Myeloid Leukemia (AML) is a rapidly progressing hematologic malignancy with poor treatment outcomes and a high relapse rate.
  • Natural Killer (NK) cells possess potent anti-tumor activity against AML, but their efficacy is compromised by disease-associated cellular defects.
  • Tumor cells in AML often evade NK cell-mediated lysis by downregulating HLA ligands, which are crucial for activating NK cell receptors.

Purpose of the Study:

  • To review the role of NK cell defects in the progression of Acute Myeloid Leukemia.
  • To discuss emerging NK cell-based therapies for AML, including adoptive transfer and CAR-NK cells.
  • To summarize current preclinical and clinical trial data on NK cell therapies in AML.

Main Methods:

  • Review of existing literature on NK cell function and defects in AML.
  • Analysis of data from preclinical studies and clinical trials involving various NK cell-based therapeutic strategies.
  • Discussion of cell surface markers associated with NK cell dysfunction in AML.

Main Results:

  • NK cell cytotoxicity against AML is frequently impaired by disease mechanisms, including reduced expression of activating ligand targets.
  • Various NK cell therapies, such as adoptive transfer and CAR-NK cells, are being investigated for AML treatment.
  • Current data on NK cell therapies in AML show variable outcomes, with remissions often being transient.

Conclusions:

  • NK cell defects represent a significant barrier to effective AML treatment and contribute to disease progression and relapse.
  • While promising, NK cell therapies for AML require further optimization and validation to improve long-term efficacy.
  • Continued research into NK cell biology and therapeutic applications is crucial for developing more effective treatments for Acute Myeloid Leukemia.